The FINANCIAL — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), on May 10 announced the signing of a license agreement with UK-based Cell Therapy Ltd. (hereafter, CTL) for an exclusive license in Japan to develop and market Heartcel, a immune-modulatory progenitor (iMP) cell therapeutic agent for ischemic heart failure currently in development.
Heartcel is an allogeneic iMP cell therapeutic agent created using a new CTL proprietary method. Heartcel is to be injected into the cardiac muscle for expected therapeutic effects in patients suffering from ischemic heart failure, according to Daiichi Sankyo.
In Japan, Daiichi Sankyo will develop and market Heartcel, while CTL will maintain manufacturing responsibilities for clinical trials and commercialization. Daiichi Sankyo will make a lump-sum payment to CTL on the signing of the agreement, followed by future milestone and sales royalty payments.
Discussion about this post